Ratings by BMO Capital (David Lebowitz)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/18/2026 | Aktis Oncology | AKTS | New Coverage | Outperform (N/A) |
24.72 (25.64) |
3.72% | Details | |
| 8/18/2026 | Bicara Therapeutics Inc | BCAX | New Coverage | Outperform (N/A) |
24.94 (23.75) |
-4.77% | Details | |
| 8/18/2026 | Alnylam Pharmaceuticals | ALNY | New Coverage | Outperform (N/A) |
224.60 (235.27) |
4.75% | Details | |
| 8/18/2026 | Ascendis Pharma | ASND | New Coverage | Outperform (N/A) |
247.40 (251.25) |
1.56% | Details | |
| 8/18/2026 | Perspective Therapeutics Inc | CATX | New Coverage | Outperform (N/A) |
3.22 (3.20) |
-0.62% | Details | |
| 8/18/2026 | Prime Medicine | PRME | New Coverage | Outperform (N/A) |
3.17 (3.29) |
3.79% | Details | |
| 8/18/2026 | Ionis Pharmaceuticals | IONS | New Coverage | Market Perform (N/A) |
58.63 (61.48) |
4.86% | Details | |
| 8/18/2026 | BioMarin Pharmaceutical Inc. | BMRN | New Coverage | Outperform (N/A) |
66.64 (65.19) |
-2.18% | Details | |
| 8/18/2026 | Exelixis | EXEL | New Coverage | Market Perform (N/A) |
52.32 (54.37) |
3.92% | Details |
